Dr. Helge Lubenow
Dr. Helge Lubenow (*1968, German) studied Biology and earned the doctoral degree at the University of Cologne and the Max-Planck-Institute in the field of genetics.
After joining Qiagen GmbH, Germany, in 1997, Dr. Lubenow held various positions, including Senior Vice President and head of molecular diagnostic business (2011 to 2015). During this time, Dr. Lubenow assumed positions in enterprises newly acquired by Qiagen GmbH, such as Corbett Life Science, Sydney and Brisbane, Australia and Digene Inc., Gaithersburg, U.S.A. and was responsible for restructuring or integration of the respective enterprise. In 2016, Dr. Lubenow founded her own consulting firm AGOS Consulting. From 2018 to 2019 she was the managing director of tesa Labtec GmbH a wholly owned subsidiary of Beiersdorf AG. 2020 through May 2023 she was appointed as CEO of Proteomedix AG, Zurich, Switzerland, an organization which she had served as a member of the board since 2017. Dr. Lubenow has many years of experience in the field of molecular diagnostics within a broad network in the health sector, in management consulting and as an expert for the in vitro diagnostics industry in Europe, Asia and the United States.
Dr. Lubenow has been a Supervisory Board member of Epigenomics AG since June 2016 and has been appointed chairwoman in February 2023. She is an independent member (within the meaning of the German Corporate Governance Code). Dr. Lubenow’s current appointment ends in 2024.
Dr. Lubenow is a member of the legally required supervisory boards of the following companies: Biofrontera AG, Leverkusen, Germany.
Dr. Lubenow is a member of the following comparable control committees of domestic and foreign companies: Neracare GmbH, Frankfurt am Main, Germany; Human Gesellschaft für Biochemica und Diagnostica mbH, Wiesbaden, Germany; Avelo AG, Schlieren, Switzerland.